The global cervical cancer diagnostics market size is expected to reach USD 12.69 Billion in 2030 and register a revenue CAGR of 5.8% over the forecast period, according to latest report by Reports and Data. Steady revenue growth of the market can be attributed to several factors, such as growing awareness about cervical cancer screening and technological advancements in diagnosis. However, high costs associated with cervical cancer diagnostics may hamper market revenue growth over the forecast period.

Cervical cancer is the fourth-most common cancer and cause of cancer deaths in women worldwide. In 2018, 570,000 cases of cervical cancer were recorded, with over 300,000 deaths, and it accounts for around 8% of both total cancer cases and total cancer deaths in women. Approximately, 80% of cervical cancer occurs in developing countries, as per data from WHO, and it is the most frequently detected cancer during pregnancy. Hence, early diagnosis of cervical cancer is essential to initiate early treatment and thus, reduce mortality rates. Various testing procedures are available for the diagnosis of cervical cancer, but the most accessible and easy testing method is the pap smear test.

 Cervical Cancer Diagnostics Market Overview:

The pharma and healthcare industry has undergone a revolutionary change owing to the COVID-19 pandemic with individuals increasing their focus on health and wellness. Companies operating in the industry have invested heavily in clinical trials and research studies to develop medications to cater to the growing unmet clinical demand on a global level. Implementation of cutting-edge technology in healthcare sector and increasing investment in research and development have contributed significantly to revenue growth of the market in the recent past. In addition, availability of favorable health insurance and reimbursement policies have also positively impacted the healthcare sector with more and more individuals opting to get treatment at hospital and clinical facilities. Rapid development of novel drugs and pharmaceuticals, increasing incidence of lifestyle and chronic diseases, establishment of state-of-the-art healthcare facilities, and rising availability of over-the-counter medications have significantly contributed to the revenue growth of the market.  

Further key findings from the report suggest:

• Among therapy segments, chemotherapy segment accounted for largest revenue share in 2021. Chemotherapy is a drug treatment that uses powerful chemicals to destroy fast growing cells in the body, and is most often used to treat cancer. It is used in different ways to treat cancer patients, and is quite effective, as it doesn’t require any supplementary treatment to cure cancer. Additionally, it can relieve signs and symptoms of cancer as well.
• Among therapy segments, the radiation therapy segment is expected to register a faster revenue CAGR during the forecast period, due to increasing adoption of radiation therapy, as it can completely eliminate cancer cells from the body by using high energy X-rays. The therapy can be used as an alternative to surgical interventions in the early stages of cancer. The specific therapy given to patients of cervical cancer depends on several factors, such as health of the woman, stage of the cancer, tolerance capacity, side effects of the therapy, and overall fitness of the patient. Several cancer treatments or therapies are given in combination with internal radiation therapy to achieve maximum results, which is expected to drive segment revenue growth.
• Cervical cancer diagnostics market in North America accounted for largest revenue share in 2021, due to technological developments in the healthcare industry. Presence of an advanced medical sector in the region is playing a pivotal role in facilitating extensive research development activities for innovative product launches. Rising investments in allied industries, such as pharmaceuticals and biotechnology, are contributing significantly to the growth of this market. Moreover, several key market players have their headquarters in countries in the region, which is further driving overall market growth. Additionally, countries such as the U.S. and Canada have high prevalence of cervical cancer, and so there is increasing demand for novel and effective diagnostic and therapeutic modalities in the region, which is expected to drive market revenue growth in North America.
• In November 2021, Hologic Inc. completed the acquisition of Bolder Surgical, a privately held, U.S.–based company that provides advanced energy vessel sealing surgical devices. This acquisition focuses on expanding Hologic’s growing laparoscopic portfolio and underscores their commitments to women’s health. Hologic, Inc. is an innovative medical technology company focusing primarily on improving women’s health and well-being through early detection and treatment of diseases.

 Top Companies Profiled in the Report Include:

Abbott Laboratories Ltd., Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Guided Therapeutics Inc., Hologic Inc., Qiagen N.V., Quest Diagnostics Inc., CooperSurgical Inc., and Arbor Vita Corporation. 

Additionally, the report consists a detailed analysis of the segmentation of the PTA Balloon Cathetery tests Market based on product types and end-use/application offered in the PTA Balloon Cathetery tests Market –

Test Type Outlook (Revenue, USD Billion; 2019–2030)

• Pap Smear Tests
• Colposcopy
• HPV Testing
• Biopsy and Endocervical curettage
• Others

End-use Outlook (Revenue, USD Billion; 2019–2030)

• Hospitals and Clinics
• Laboratories
• Diagnosing Centers
• Others

Therapy Outlook (Revenue, USD Billion; 2019–2030)

• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy

Key Regional Markets Studied in the Report:

• North America (U.S., Canada)
• Europe (U.K., Italy, Germany, France, Rest of EU)
• Latin America (Chile, Brazil, Argentina, Rest of Latin America)
• Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
• The Middle East Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Request for Customization this report - https://www.reportsanddata.com/request-customization-form/1438     

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.